此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

阻止 TSC 发作和进展 2B:西罗莫司 TSC 癫痫预防研究 (TSC-STEPS)

2026年10月27日 更新者:Darcy Krueger

This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants.

This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA).

研究概览

地位

主动,不招人

详细说明

Tuberous Sclerosis Complex (TSC) is caused by genetic mutation in TSC1 or TSC2, resulting in dysregulation of the mechanistic target of rapamycin (mTOR) signaling pathway. Age at time of seizure onset in TSC infants has been linked to long-term neurodevelopmental outcome in this high-risk population. Sirolimus is an mTOR inhibitor used to treat many of the symptoms of TSC, including epilepsy. This will be the first study to truly evaluate a targeted, disease-modifying drug therapy for preventing or delaying seizure onset in TSC using a rational, mechanism-based therapeutic approach.

研究类型

介入性

注册 (估计的)

64

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alabama
      • Birmingham、Alabama、美国、35294
        • University of Alabama at Birmingham
    • California
      • Los Angeles、California、美国、90095
        • University of California at Los Angeles
      • Palo Alto、California、美国、94304
        • Stanford University
    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • Boston Children's Hospital
    • North Carolina
      • Chapel Hill、North Carolina、美国、27510
        • University of North Carolina at Chapel Hill
    • Ohio
      • Cincinnati、Ohio、美国、45229
        • Cincinnati Children's Hospital Medical Center
    • Texas
      • Houston、Texas、美国、77030
        • University of Texas HSC at Houston
    • Washington
      • Seattle、Washington、美国、98105
        • Seattle Children's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1天 至 6个月 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. 0-6 months of age at the time of enrollment (subject must be <7 months of chronological age at time of randomization and treatment initiation). Corrected age must be at least 39 weeks (calculated by subtracting the number of weeks born before 40 weeks gestation from the chronological age).
  2. Has a confirmed diagnosis of TSC based on established clinical or genetic criteria

Exclusion Criteria:

  1. Prior history of seizures (clinical or electrographic) at the time of enrollment or identified on baseline EEG.
  2. Has been treated in the past or is currently being treated at the time of enrollment with conventional anticonvulsant medications (AEDs), systemic (oral) mTOR inhibitors (such as rapamycin, sirolimus, or everolimus), ketogenic-related special diet, or another anti-seizure therapeutic agent, device, or procedure.
  3. Has taken any other investigational drug as part of another research study, within 30 days prior to the baseline screening visit.
  4. Has a significant illness or active infection at the time of the baseline screening visit
  5. Has a history of significant prematurity, defined as gestational age <30 weeks at the time of delivery, or other significant medical complications at birth or during the neonatal period that other than TSC would convey additional risk of seizures or neurodevelopmental delay (i.e. HIE, severe neonatal infection, major surgery, prolonged ventilatory or other life-saving supportive care or procedures).
  6. Abnormal laboratory values at baseline (i.e., renal function, liver function, or bone marrow production) that are in the opinion of the investigator clinically significant and may jeopardize the safety of the study subject.
  7. Prior, planned or anticipated neurosurgery within 3 months of the baseline visit
  8. Has a TSC-associated condition for which mTOR treatment is clinically indicated (i.e. SEGA or AML).
  9. Subjects who are, in the opinion of the investigator, unable to comply with the requirements of the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Placebo

Placebo

Matching placebo

实验性的:Sirolimus

Sirolimus

The investigational drug product to be used in this study is sirolimus, provided in oral suspension.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Efficacy -- time to seizure onset
大体时间:12 months of age

Time to seizure onset, comparing sirolimus with placebo

12 months of age
Safety -- adverse events
大体时间:12 months of age

Percentage of subjects reporting severe (CTCAE v5.0 grade >= 3) adverse event (AE) or serious adverse event (SAE), comparing sirolimus with placebo.

12 months of age

次要结果测量

结果测量
措施说明
大体时间
Neurodevelopmental Outcomes
大体时间:12 and 24 months of age

Neurodevelopmental outcomes at the end of treatment, comparing sirolimus with placebo.

12 and 24 months of age
Quality of Life Outcomes
大体时间:12 and 24 months of age

Patient and caregiver quality of life, comparing sirolimus with placebo.

12 and 24 months of age
EEG Biomarkers
大体时间:12 and 24 months of age

EEG measures of neuronal connectivity, comparing sirolimus with placebo.

12 and 24 months of age
MRI Biomarkers
大体时间:12 and 24 months of age

MRI measures of neuronal connectivity, comparing sirolimus with placebo.

12 and 24 months of age
Sirolimus Precision Dosing
大体时间:12 months of age

Validate the feasibility and effectiveness of sirolimus precision dosing in infants with TSC

12 months of age

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Darcy A Krueger, MD, PhD、Children's Hospital Medical Center, Cincinnati
  • 首席研究员:Martina Bebin, MD, MPA、University of Alabama at Birmingham

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年10月13日

初级完成 (估计的)

2027年6月30日

研究完成 (估计的)

2028年6月30日

研究注册日期

首次提交

2021年10月22日

首先提交符合 QC 标准的

2021年10月22日

首次发布 (实际的)

2021年11月3日

研究记录更新

最后更新发布 (实际的)

2026年10月29日

上次提交的符合 QC 标准的更新

2026年10月27日

最后验证

2026年10月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅